Jonathan S. Zager, MD

C-POST shows adjuvant cemiplimab cuts recurrence risk in high‑risk cutaneous SCC after surgery and radiation, reshaping multidisciplinary care.

Learn red flags for advanced cutaneous SCC and how PD‑1/PD‑L1 immunotherapy offers durable responses, reshaping treatment beyond surgery.

Learn when high-risk skin SCC needs early oncology referrals, imaging, and coordinated tumor-board care to avoid delays and improve outcomes.

Learn how clinicians spot aggressive cutaneous squamous cell carcinoma and when multidisciplinary care and immunotherapy improve outcomes.

Jonathan S. Zager, MD, discussed the use of percutaneous hepatic perfusion vs best alternative care for patients with hepatic-dominant ocular melanoma analyzed in the phase 3 FOCUS trial.

CLND as standard of care for patients with SLN-positive metastatic melanoma is supported by a wealth of compelling prospective data.